Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

Published Date: 08 Jul 2024

Joseph Mikhael, MD, leads a discussion on the DREAMM-7 and DREAMM-8 trials

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

2.

Study finds common genetic target may halt breast cancer cell growth

3.

New study highlights success of financial toxicity tumor board in reducing cancer treatment costs

4.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot